InvestorsHub Logo
Followers 58
Posts 10034
Boards Moderated 1
Alias Born 09/21/2016

Re: None

Saturday, 07/30/2022 9:54:35 AM

Saturday, July 30, 2022 9:54:35 AM

Post# of 458270
Study of the mechanism of action of Blarcamesine (ANAVEX®2-73):

Whole blood transcriptomics analysis identifies treatment impact on compensatory pathways by restoring key neurodegenerative pathways functionality, including Alzheimer’s disease pathway

Virtual Platform
Sun, Jul 31
7:00am - 11:55pm (Pacific)

Author Block: Coralie Williams, MSc1; Martin Kindermans, MSC1; Frédéric Parmentier, PhD1; Federico Goodsaid, PhD1; Edward Hammond, MD, PhD, MPH2; Christopher U Missling, PhD2 and Mohammad Afshar, MD, PhD1, (1)Ariana Pharma, Paris, France, (2)Anavex Life Sciences Corp., New York, NY, USA
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News